Company: PRGO
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001585364-25-000122
Chunk: 198

Company: PERRIGO Co plc
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 7
Chunk 198
---
 to the prior year.

CSCA net sales by product category were as follows:

SalesSix Months Ended(in millions, except percentages)June 28, 2025June 29, 2024$ Change% ChangeUpper Respiratory$261.2 $249.1 $12.1 4.9 %Digestive Health212.7 248.2 (35.5)(14.3)%Nutrition200.3 176.7 23.6 13.4 %Pain and Sleep-Aids156.8 164.2 (7.4)(4.5)%Healthy Lifestyle144.1 140.4 3.7 2.6 %Oral Care122.0 137.9 (15.9)(11.5)%Skin Care106.3 106.7 (0.4)(0.4)%Women's Health33.7 44.0 (10.3)(23.4)%VMS3.8 9.5 (5.7)(60.0)%Other CSCA1.8 1.6 0.2 12.5 %Total CSCA$1,242.8 $1,278.3 $(35.5)(2.8)%

Sales drivers in each category are provided below: 

•Upper Respiratory: Net sales of $261.2 million increased 4.9% due primarily to higher incidence levels of cough cold compared to the prior year first quarter, higher net sales of allergy products, including Nasonex®, Fluticasone and Fexofenadine, and new business wins. This growth was partially offset by previously disclosed net lost distribution of lower margin products;

•Digestive Health: Net sales of $212.7 million decreased 14.3% due primarily to previously disclosed net lost distribution of lower margin products in U.S. Store Brand and lower consumption of proton pump inhibitors, including Omeprazole, Esomeprazole and Lansoprazole, despite Perrigo share gains. These impacts more than offset higher net sales of Polyethylene Glycol;

45

Perrigo Company plc - Item 2CSCA

•Nutrition: Net sales of $200.3 million increased 13.4% due primarily to a 14% increase in net sales of infant formula products driven by continuing store brand infant formula business recovery partially offset by lower net sales in the Good